Plausibility of therapeutic effects of Rho kinase inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (COVID-19).

Abedi, Farshad; Rezaee, Ramin; Karimi, Gholamreza

Abedi, Farshad; Rezaee, Ramin; Karimi, Gholamreza.

Afiliação

Abedi F; Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran.
Rezaee R; Clinical Research Unit, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Neurogenic Inflammation Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.
Karimi G; Pharmaceutical Research Center, Institute of Pharmaceutical Technology, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmacodynamics and Toxicology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: karimig@mums.ac.ir.

Pharmacol Res ; 156: 104808, 2020 06.

Article em En | MEDLINE | ID: mdl-32283223

Assuntos

Betacoronavirus; Infecções por Coronavirus/tratamento farmacológico; Pneumonia Viral/tratamento farmacológico; Inibidores de Proteínas Quinases/uso terapêutico; Quinases Associadas a rho/antagonistas & inibidores; COVID-19; Humanos; Pandemias; SARS-CoV-2; Transdução de Sinais/efeitos dos fármacos; Tratamento Farmacológico da COVID-19

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Pneumonia Viral / Infecções por Coronavirus / Inibidores de Proteínas Quinases / Quinases Associadas a rho / Betacoronavirus Limite: Humans Idioma: En Revista: Pharmacol Res Assunto da revista: FARMACOLOGIA Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Irã

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google